我们正在寻找中国人参与临床研究
News
AKL & HAM - 0800 788 3437
CHC & WLG - 0800 862 278

Important Information

If you are interested in applying for this study, please:
  • read the study description and study information document
  • review the Visit Planner dates in your location and confirm that you are available for the stated dates.
  • If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
  • If you have already registered with us, answer the pre-screening questions listed below and submit your interest.

We will then contact you to check your suitability.

Study Description

New Zealand Clinical Research is studying an investigational medicine that could help people with obesity.

Obesity is a disease that is associated with a wide range of health issues, including diabetes, heart disease, stroke, arthritis, and some cancers. In New Zealand, approximately 1 in 3 adults and 1 in 10 children are classified as obese, and approximately 890 million adults are living with obesity worldwide.

Lifestyle modification, including diet, exercise, and behavioural change, remain key in the initial management of obesity. Any weight loss achieved with lifestyle interventions alone is challenging to maintain.

GLP-1 receptor agonists (such as semaglutide (Ozempic®)) are currently popular medications used manage obesity and diabetes. However, body weight tends to rebound quickly after stopping, requiring ongoing use of these medications to maintain weight loss. Studies show that 25% to 45% of weight loss from using these medications comes from the reduction of bones and muscle. This raises concerns about the potential negative side effects of GLP-1–based medications on physical function and possible treatment-induced physical weakness or “frailty”.

BC-006 is a type of investigational medication called a small interfering ribonucleic acid (siRNA). It works in the liver to reduce the productions of a protein called inhibin subunit beta E (INHBE). Studies to date have shown that reducing INHBE can reduce fat mass and improve metabolism (how fast your body burns calories). Unlike GLP-1 receptor agonists, medications that inhibit (reduce) INHBE have the potential to preserve muscle and bone mass. Therefore, if BC-006 can reduce levels of INHBE in the body, it may be an effective treatment to help prevent rebound weight gain after discontinuing medications like semaglutide.

Part 1 of the study will investigate the effects of a single ascending doses (SAD) of BC-006 in adult participants with obesity.

This is an investigational medication because it has not been approved by MedSafe or other drug regulatory authorities.

This study (2025 FULL 22086) is being funded by BaseCure Therapeutics Inc. and has been approved by the Health and Disability Ethics Committee (HDEC).

Requirements

Healthy Males and Females

  • Aged between 18-65 years
  • BMI (Body Mass Index) between 30 – 40 kg/m2
  • Have had a stable body weight for at least 3 months prior to Screening
  • In good general health and does not have any significant medical conditions (including but not limited to diabetes, kidney disease, or history of pancreatitis)
  • Smokers/Vapers of 5 cigarettes (or equivalent) or less per day allowed
  • Not currently taking any regular prescription medications (except for blood pressure medications)
  • Have not taken GLP-1 based therapies e.g. Trulicity, Victoza or Saxenda, within 12 months.

What is Involved?

Study Visits: 3-night stay + 8 clinic visits
Reimbursement: Up to $4,000 before tax

Important Documents

Important documents to download and read

Pre-screening Form

HIBISCUS

Pre screening for HIBISCUS

Personal details

Please provide your name, email and phone number so we can contact you
NZCR Site(Required)
Which site are you located at? PLEASE NOTE: This study is currently only taking place at our Christchurch site and we are not recruiting outside of Canterbury.

Medical questions

Have you had any covid symptoms in the last 4 weeks or been in isolation?
Have you previously participated in a study with NZCR or any other organisation?
This study requires the use of contraception during the study. If you are in a heterosexual relationship both partners must agree to use contraception (condoms for males | IUD, birth control or another approved form for females). Are you currently using 2 forms of contraception?
Have you donated blood or plasma in the last 56 days? If yes please provide details
Have you received any vaccinations in the last 14 days?
Do you have any History of Diabetes?
Have you had any history of skin diseases such as rash, food allergies, psoriasis or hives?
Any history of abnormal liver or kidney conditions?
Do you have any significant heart disease or heart related conditions/abnormalities? Do you have any family history of heart conditions?
Do you have any history of allergies, asthma, hay fever, food allergies etc that you are aware of?
Any significant history of acid reflux or peptic (stomach) ulcers?
Do you have any history of clinically significant acute systemic infection and/or antibiotic treatment within 28 days?
Have you been sick in the last 30 days?
Have you ever undergone any gastric or intestinal surgery? For example, gastric bypass and gastric sleeve.
Do you have any history of medical conditions relating to:(Required)
If you have none, please select the last option.
Have you taken any prescription, vitamins, supplements, pharmacy medication or over the counter medications in the last 28 days? Please include any Vaccines in the last 3 months
Have you looked at the study dates and are okay to come in those days? Indicate which group/s you are available for. This means having flexibility for more than one group increases your chances of being accepted into a group.
Just to inform you, that you come in for screening at risk. There is no payment for the screening visit, and you may not be offered a position on the study if the group fills up. It is not guaranteed that you will get a full position on the study as it depends on your results as well. Are you comfortable with this?
Pre-screening form policy(Required)
I understand that by submitting this form, NZCR will use the information for pre-screening purposes for this study. This information may be recorded on your profile to allow us to improve our process when screening you for a future study. All information provided is confidential. I also understand that by submitting this form, I will be receiving emails, texts or calls about this study. For more information, please refer to the Privacy Policy.